Mainstay Medical International plc announced Jason Hannon has taken up his role as CEO and been appointed as a Director of Mainstay. Mr. Hannon joins Mainstay at a critical time in the company's development with the dual focus of commercializing the market-changing ReActiv8 technology in Europe and beyond, while simultaneously completing the global clinical trial in support of submission for FDA approval.